Table 1 Baseline patient characteristics
Variable | ARB Group (n = 162) | Non-ARB Group (n = 245) | P value |
|---|---|---|---|
Age (years) | 60.8 ± 9.5 | 60.5 ± 10.1 | 0.751 |
Men | 107 (66.0%) | 195 (79.6%) | 0.002 |
Body mass index (kg/m2) | 24.7 ± 4.3 | 24.9 ± 4.2 | 0.372 |
Risk factors | |||
Diabetes | 55 (34.0%) | 68 (28.1%) | 0.21 |
Hyperlipidemia | 64 (39.5%) | 101 (41.2%) | 0.119 |
Current smoker | 38 (23.9%) | 67 (27.7%) | 0.208 |
Family History of CAD | 4 (2.5%) | 5 (2.1%) | 0.766 |
History of CVA | 3 (1.9%) | 4 (1.6%) | 1 |
LVEF (%) | 55 ± 5 | 54 ± 4 | 0.673 |
Mean follow-up duration (months) | 19.0 ± 11.4 | 20.3 ± 14.1 | 0.523 |
ARBs | |||
Candesartan | 34 (21.0%) | ||
Valsartan | 29 (17.9%) | ||
Irbesartan | 34 (21.0%) | ||
Telmisartan | 10 (6.2%) | ||
Losartan | 31 (19.1%) | ||
Olmesartan | 15 (9.3%) | ||
Eprosartan | 10 (6.2%) | ||
Medications | |||
Aspirin | 160 (98.8%) | 235 (95.9%) | 0.859 |
Clopidogrel | 106 (65.4%) | 169 (69.0%) | 0.582 |
Statins | 153 (94.4%) | 237 (96.7%) | 0.775 |
Beta blocker | 34 (21.0%) | 51 (20.8%) | 0.218 |
Calcium channel blockers | 39 (24.1%) | 169 (68.9%) | <0.001 |
Diuretics | 17 (10.5%) | 27 (11.0%) | 0.947 |